Efficacy	O
of	O
peptide	B:C0206473
receptor	I:C0206473
radionuclide	O
therapy	I:C0203608
with	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
metastatic	O
pulmonary	O
neuroendocrine	O
tumors	I:C0206754
:	O
a	O
dual	O
-	O
centre	O
analysis	O
.	O

Efficacy	O
of	O
peptide	O
receptor	I:C0206473
radionuclide	B:C0203608
therapy	I:C0203608
with	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
metastatic	O
pulmonary	O
neuroendocrine	O
tumors	I:C0206754
:	O
a	O
dual	O
-	O
centre	O
analysis	O
.	O

Efficacy	O
of	O
peptide	O
receptor	I:C0206473
radionuclide	O
therapy	I:C0203608
with	O
(	B:C1254351
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
metastatic	O
pulmonary	O
neuroendocrine	O
tumors	I:C0206754
:	O
a	O
dual	O
-	O
centre	O
analysis	O
.	O

Efficacy	O
of	O
peptide	O
receptor	I:C0206473
radionuclide	O
therapy	I:C0203608
with	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
metastatic	O
pulmonary	B:C0024109
neuroendocrine	O
tumors	I:C0206754
:	O
a	O
dual	O
-	O
centre	O
analysis	O
.	O

Efficacy	O
of	O
peptide	O
receptor	I:C0206473
radionuclide	O
therapy	I:C0203608
with	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
metastatic	O
pulmonary	O
neuroendocrine	B:C0206754
tumors	I:C0206754
:	O
a	O
dual	O
-	O
centre	O
analysis	O
.	O

Efficacy	O
of	O
peptide	O
receptor	I:C0206473
radionuclide	O
therapy	I:C0203608
with	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
metastatic	O
pulmonary	O
neuroendocrine	O
tumors	I:C0206754
:	O
a	O
dual	O
-	O
centre	O
analysis	B:C0936012
.	O

There	O
is	O
lack	O
of	O
data	O
on	O
the	O
specific	O
benefit	O
of	O
peptide	B:C0206473
receptor	I:C0206473
radionuclide	O
therapy	I:C0203608
(	O
peptide	O
receptor	I:C0203608
radionuclide	I:C0203608
therapy	I:C0203608
)	O
in	O
neuroendocrine	O
tumors	I:C0206754
(	O
neuroendocrine	O
tumors	I:C0206754
)	O
of	O
pulmonary	O
origin	O
.	O

There	O
is	O
lack	O
of	O
data	O
on	O
the	O
specific	O
benefit	O
of	O
peptide	O
receptor	I:C0206473
radionuclide	B:C0203608
therapy	I:C0203608
(	O
peptide	O
receptor	I:C0203608
radionuclide	I:C0203608
therapy	I:C0203608
)	O
in	O
neuroendocrine	O
tumors	I:C0206754
(	O
neuroendocrine	O
tumors	I:C0206754
)	O
of	O
pulmonary	O
origin	O
.	O

There	O
is	O
lack	O
of	O
data	O
on	O
the	O
specific	O
benefit	O
of	O
peptide	O
receptor	I:C0206473
radionuclide	O
therapy	I:C0203608
(	O
peptide	B:C0203608
receptor	I:C0203608
radionuclide	I:C0203608
therapy	I:C0203608
)	O
in	O
neuroendocrine	O
tumors	I:C0206754
(	O
neuroendocrine	O
tumors	I:C0206754
)	O
of	O
pulmonary	O
origin	O
.	O

There	O
is	O
lack	O
of	O
data	O
on	O
the	O
specific	O
benefit	O
of	O
peptide	O
receptor	I:C0206473
radionuclide	O
therapy	I:C0203608
(	O
peptide	O
receptor	I:C0203608
radionuclide	I:C0203608
therapy	I:C0203608
)	O
in	O
neuroendocrine	B:C0206754
tumors	I:C0206754
(	O
neuroendocrine	O
tumors	I:C0206754
)	O
of	O
pulmonary	O
origin	O
.	O

There	O
is	O
lack	O
of	O
data	O
on	O
the	O
specific	O
benefit	O
of	O
peptide	O
receptor	I:C0206473
radionuclide	O
therapy	I:C0203608
(	O
peptide	O
receptor	I:C0203608
radionuclide	I:C0203608
therapy	I:C0203608
)	O
in	O
neuroendocrine	O
tumors	I:C0206754
(	O
neuroendocrine	B:C0206754
tumors	I:C0206754
)	O
of	O
pulmonary	O
origin	O
.	O

There	O
is	O
lack	O
of	O
data	O
on	O
the	O
specific	O
benefit	O
of	O
peptide	O
receptor	I:C0206473
radionuclide	O
therapy	I:C0203608
(	O
peptide	O
receptor	I:C0203608
radionuclide	I:C0203608
therapy	I:C0203608
)	O
in	O
neuroendocrine	O
tumors	I:C0206754
(	O
neuroendocrine	O
tumors	I:C0206754
)	O
of	O
pulmonary	B:C0024109
origin	O
.	O

This	O
dual	O
-	O
centre	O
study	B:C2603343
aimed	O
to	O
assess	O
outcome	O
and	O
toxicity	O
of	O
standardized	O
peptide	O
receptor	I:C0203608
radionuclide	I:C0203608
therapy	I:C0203608
with	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
a	O
patient	O
population	O
of	O
advanced	O
pulmonary	O
neuroendocrine	O
tumors	I:C0206754
of	O
grade	O
1	I:C0441800
-	I:C0441800
2	I:C0441800
.	O

This	O
dual	O
-	O
centre	O
study	O
aimed	O
to	O
assess	O
outcome	O
and	O
toxicity	B:C0600688
of	O
standardized	O
peptide	O
receptor	I:C0203608
radionuclide	I:C0203608
therapy	I:C0203608
with	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
a	O
patient	O
population	O
of	O
advanced	O
pulmonary	O
neuroendocrine	O
tumors	I:C0206754
of	O
grade	O
1	I:C0441800
-	I:C0441800
2	I:C0441800
.	O

This	O
dual	O
-	O
centre	O
study	O
aimed	O
to	O
assess	O
outcome	O
and	O
toxicity	O
of	O
standardized	O
peptide	B:C0203608
receptor	I:C0203608
radionuclide	I:C0203608
therapy	I:C0203608
with	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
a	O
patient	O
population	O
of	O
advanced	O
pulmonary	O
neuroendocrine	O
tumors	I:C0206754
of	O
grade	O
1	I:C0441800
-	I:C0441800
2	I:C0441800
.	O

This	O
dual	O
-	O
centre	O
study	O
aimed	O
to	O
assess	O
outcome	O
and	O
toxicity	O
of	O
standardized	O
peptide	O
receptor	I:C0203608
radionuclide	I:C0203608
therapy	I:C0203608
with	O
(	B:C1254351
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
a	O
patient	O
population	O
of	O
advanced	O
pulmonary	O
neuroendocrine	O
tumors	I:C0206754
of	O
grade	O
1	I:C0441800
-	I:C0441800
2	I:C0441800
.	O

This	O
dual	O
-	O
centre	O
study	O
aimed	O
to	O
assess	O
outcome	O
and	O
toxicity	O
of	O
standardized	O
peptide	O
receptor	I:C0203608
radionuclide	I:C0203608
therapy	I:C0203608
with	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
a	O
patient	O
population	O
of	O
advanced	O
pulmonary	B:C0024109
neuroendocrine	O
tumors	I:C0206754
of	O
grade	O
1	I:C0441800
-	I:C0441800
2	I:C0441800
.	O

This	O
dual	O
-	O
centre	O
study	O
aimed	O
to	O
assess	O
outcome	O
and	O
toxicity	O
of	O
standardized	O
peptide	O
receptor	I:C0203608
radionuclide	I:C0203608
therapy	I:C0203608
with	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
a	O
patient	O
population	O
of	O
advanced	O
pulmonary	O
neuroendocrine	B:C0206754
tumors	I:C0206754
of	O
grade	O
1	I:C0441800
-	I:C0441800
2	I:C0441800
.	O

This	O
dual	O
-	O
centre	O
study	O
aimed	O
to	O
assess	O
outcome	O
and	O
toxicity	O
of	O
standardized	O
peptide	O
receptor	I:C0203608
radionuclide	I:C0203608
therapy	I:C0203608
with	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
a	O
patient	O
population	O
of	O
advanced	O
pulmonary	O
neuroendocrine	O
tumors	I:C0206754
of	O
grade	B:C0441800
1	I:C0441800
-	I:C0441800
2	I:C0441800
.	O

We	O
retrospectively	O
assessed	O
22	O
consecutively	O
patients	O
treated	B:C0332293
with	I:C0332293
4	O
intended	O
cycles	O
at	O
3	O
monthly	O
intervals	O
(	O
mean	O
activity	O
per	O
cycle	O
7.8±0.68	O
GBq	O
)	O
.	O

In	O
a	O
median	O
follow	B:C1522577
-	I:C1522577
up	I:C1522577
period	O
of	O
54	O
months	O
,	O
no	O
significant	O
nephrotoxicity	O
(	O
≥	O
grade	O
3	I:C0441800
)	O
was	O
observed	O
.	O

In	O
a	O
median	O
follow	O
-	I:C1522577
up	I:C1522577
period	O
of	O
54	O
months	O
,	O
no	O
significant	O
nephrotoxicity	B:C0599918
(	O
≥	O
grade	O
3	I:C0441800
)	O
was	O
observed	O
.	O

In	O
a	O
median	O
follow	O
-	I:C1522577
up	I:C1522577
period	O
of	O
54	O
months	O
,	O
no	O
significant	O
nephrotoxicity	O
(	O
≥	O
grade	B:C0441800
3	I:C0441800
)	O
was	O
observed	O
.	O

Reversible	O
hematotoxicity	B:C0920103
(	O
grade	O
3	I:C0441800
)	O
occurred	O
in	O
3	O
patients	O
(	O
13.6	O
%	O
)	O
.	O

Reversible	O
hematotoxicity	O
(	O
grade	B:C0441800
3	I:C0441800
)	O
occurred	O
in	O
3	O
patients	O
(	O
13.6	O
%	O
)	O
.	O

Treatment	B:C0521982
response	I:C0521982
consisted	O
of	O
partial	O
response	O
in	O
6	O
(	O
27.3	O
%	O
)	O
,	O
stable	O
disease	I:C0677946
in	O
9	O
(	O
40.9	O
%	O
)	O
,	O
and	O
progressive	O
disease	I:C1335499
in	O
7	O
(	O
31.8	O
%	O
)	O
patients	O
.	O

Treatment	O
response	I:C0521982
consisted	O
of	O
partial	O
response	O
in	O
6	O
(	O
27.3	O
%	O
)	O
,	O
stable	B:C0677946
disease	I:C0677946
in	O
9	O
(	O
40.9	O
%	O
)	O
,	O
and	O
progressive	O
disease	I:C1335499
in	O
7	O
(	O
31.8	O
%	O
)	O
patients	O
.	O

Treatment	O
response	I:C0521982
consisted	O
of	O
partial	O
response	O
in	O
6	O
(	O
27.3	O
%	O
)	O
,	O
stable	O
disease	I:C0677946
in	O
9	O
(	O
40.9	O
%	O
)	O
,	O
and	O
progressive	B:C1335499
disease	I:C1335499
in	O
7	O
(	O
31.8	O
%	O
)	O
patients	O
.	O

High	O
hepatic	B:C0023903
tumor	I:C0023903
load	O
(>	O
50	O
%	O
)	O
and	O
high	O
plasma	O
chromogranin	I:C0055633
A	I:C0055633
(>	O
600	O
ng/	O
mL	O
)	O
were	O
negative	O
baseline	O
predictors	O
for	O
PFS	O
and	O
OS	O
on	O
univariate	O
analysis	O
,	O
CgA	O
remained	O
significant	O
on	O
multivariate	O
analysis	O
(	O
PFS	O
,	O
P=0.011	O
;	O
OS	O
,	O
P=0.026	O
)	O
.	O

High	O
hepatic	O
tumor	I:C0023903
load	O
(>	O
50	O
%	O
)	O
and	O
high	O
plasma	B:C0055633
chromogranin	I:C0055633
A	I:C0055633
(>	O
600	O
ng/	O
mL	O
)	O
were	O
negative	O
baseline	O
predictors	O
for	O
PFS	O
and	O
OS	O
on	O
univariate	O
analysis	O
,	O
CgA	O
remained	O
significant	O
on	O
multivariate	O
analysis	O
(	O
PFS	O
,	O
P=0.011	O
;	O
OS	O
,	O
P=0.026	O
)	O
.	O

High	O
hepatic	O
tumor	I:C0023903
load	O
(>	O
50	O
%	O
)	O
and	O
high	O
plasma	O
chromogranin	I:C0055633
A	I:C0055633
(>	O
600	O
ng/	O
mL	O
)	O
were	O
negative	O
baseline	O
predictors	O
for	O
PFS	O
and	O
OS	O
on	O
univariate	O
analysis	O
,	O
CgA	B:C0055633
remained	O
significant	O
on	O
multivariate	O
analysis	O
(	O
PFS	O
,	O
P=0.011	O
;	O
OS	O
,	O
P=0.026	O
)	O
.	O

Disease	B:C0242656
progression	I:C0242656
despite	O
peptide	O
receptor	I:C0203608
radionuclide	I:C0203608
therapy	I:C0203608
was	O
associated	O
with	O
shorter	O
survival	O
(	O
median	O
OS	O
15	O
vs	O
53	O
mo	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Disease	O
progression	I:C0242656
despite	O
peptide	B:C0203608
receptor	I:C0203608
radionuclide	I:C0203608
therapy	I:C0203608
was	O
associated	O
with	O
shorter	O
survival	O
(	O
median	O
OS	O
15	O
vs	O
53	O
mo	O
,	O
P	O
<	O
0.001	O
)	O
.	O

Despite	O
a	O
higher	O
incidence	O
of	O
treatment	B:C0162643
failure	I:C0162643
compared	O
to	O
neuroendocrine	O
tumors	I:C0206754
of	O
other	O
origins	O
,	O
the	O
observed	O
substantial	O
and	O
sustained	O
disease	O
stabilization	O
(	O
median	O
PFS	O
of	O
27	O
mo	O
,	O
disease	O
control	I:C0920467
rate	O
of	O
>	O
2/3	O
of	O
pts	O
)	O
indicates	O
considerable	O
efficacy	O
of	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
pulmonary	O
neuroendocrine	O
tumors	I:C0206754
.	O

Despite	O
a	O
higher	O
incidence	O
of	O
treatment	O
failure	I:C0162643
compared	O
to	O
neuroendocrine	B:C0206754
tumors	I:C0206754
of	O
other	O
origins	O
,	O
the	O
observed	O
substantial	O
and	O
sustained	O
disease	O
stabilization	O
(	O
median	O
PFS	O
of	O
27	O
mo	O
,	O
disease	O
control	I:C0920467
rate	O
of	O
>	O
2/3	O
of	O
pts	O
)	O
indicates	O
considerable	O
efficacy	O
of	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
pulmonary	O
neuroendocrine	O
tumors	I:C0206754
.	O

Despite	O
a	O
higher	O
incidence	O
of	O
treatment	O
failure	I:C0162643
compared	O
to	O
neuroendocrine	O
tumors	I:C0206754
of	O
other	O
origins	O
,	O
the	O
observed	O
substantial	O
and	O
sustained	O
disease	B:C0012634
stabilization	O
(	O
median	O
PFS	O
of	O
27	O
mo	O
,	O
disease	O
control	I:C0920467
rate	O
of	O
>	O
2/3	O
of	O
pts	O
)	O
indicates	O
considerable	O
efficacy	O
of	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
pulmonary	O
neuroendocrine	O
tumors	I:C0206754
.	O

Despite	O
a	O
higher	O
incidence	O
of	O
treatment	O
failure	I:C0162643
compared	O
to	O
neuroendocrine	O
tumors	I:C0206754
of	O
other	O
origins	O
,	O
the	O
observed	O
substantial	O
and	O
sustained	O
disease	O
stabilization	B:C1293130
(	O
median	O
PFS	O
of	O
27	O
mo	O
,	O
disease	O
control	I:C0920467
rate	O
of	O
>	O
2/3	O
of	O
pts	O
)	O
indicates	O
considerable	O
efficacy	O
of	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
pulmonary	O
neuroendocrine	O
tumors	I:C0206754
.	O

Despite	O
a	O
higher	O
incidence	O
of	O
treatment	O
failure	I:C0162643
compared	O
to	O
neuroendocrine	O
tumors	I:C0206754
of	O
other	O
origins	O
,	O
the	O
observed	O
substantial	O
and	O
sustained	O
disease	O
stabilization	O
(	O
median	O
PFS	O
of	O
27	O
mo	O
,	O
disease	B:C0920467
control	I:C0920467
rate	O
of	O
>	O
2/3	O
of	O
pts	O
)	O
indicates	O
considerable	O
efficacy	O
of	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
pulmonary	O
neuroendocrine	O
tumors	I:C0206754
.	O

Despite	O
a	O
higher	O
incidence	O
of	O
treatment	O
failure	I:C0162643
compared	O
to	O
neuroendocrine	O
tumors	I:C0206754
of	O
other	O
origins	O
,	O
the	O
observed	O
substantial	O
and	O
sustained	O
disease	O
stabilization	O
(	O
median	O
PFS	O
of	O
27	O
mo	O
,	O
disease	O
control	I:C0920467
rate	O
of	O
>	O
2/3	O
of	O
pts	O
)	O
indicates	O
considerable	O
efficacy	O
of	O
(	B:C1254351
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
pulmonary	O
neuroendocrine	O
tumors	I:C0206754
.	O

Despite	O
a	O
higher	O
incidence	O
of	O
treatment	O
failure	I:C0162643
compared	O
to	O
neuroendocrine	O
tumors	I:C0206754
of	O
other	O
origins	O
,	O
the	O
observed	O
substantial	O
and	O
sustained	O
disease	O
stabilization	O
(	O
median	O
PFS	O
of	O
27	O
mo	O
,	O
disease	O
control	I:C0920467
rate	O
of	O
>	O
2/3	O
of	O
pts	O
)	O
indicates	O
considerable	O
efficacy	O
of	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
pulmonary	B:C0024109
neuroendocrine	O
tumors	I:C0206754
.	O

Despite	O
a	O
higher	O
incidence	O
of	O
treatment	O
failure	I:C0162643
compared	O
to	O
neuroendocrine	O
tumors	I:C0206754
of	O
other	O
origins	O
,	O
the	O
observed	O
substantial	O
and	O
sustained	O
disease	O
stabilization	O
(	O
median	O
PFS	O
of	O
27	O
mo	O
,	O
disease	O
control	I:C0920467
rate	O
of	O
>	O
2/3	O
of	O
pts	O
)	O
indicates	O
considerable	O
efficacy	O
of	O
(	O
177	I:C1254351
)	I:C1254351
Lu-octreotate	I:C1254351
in	O
pulmonary	O
neuroendocrine	B:C0206754
tumors	I:C0206754
.	O

